IPP Bureau
Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment
By IPP Bureau - April 03, 2026
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
By IPP Bureau - April 03, 2026
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
By IPP Bureau - April 03, 2026
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
By IPP Bureau - April 03, 2026
Its a major breakthrough for women’s ovarian cancer care in Europe
Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
By IPP Bureau - April 03, 2026
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
By IPP Bureau - April 03, 2026
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
Nearly 40 industry groups unite to push for EU Biotech Act II
By IPP Bureau - April 03, 2026
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
By IPP Bureau - April 03, 2026
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
EMA moves to cut animal testing with “virtual control groups” in preclinical research
By IPP Bureau - April 03, 2026
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies
By IPP Bureau - April 03, 2026
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
By IPP Bureau - April 03, 2026
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech
By IPP Bureau - April 03, 2026
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students
By IPP Bureau - April 03, 2026
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Marksans Pharma receives USFDA approval for Benzonatate capsules
By IPP Bureau - April 02, 2026
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
Saharsh Davuluri takes over as CEO & MD of Neuland Laboratories
By IPP Bureau - April 02, 2026
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
